Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism

The purpose of this study is to determine whether autologous bone marrow mononuclear cells transplantation after stroke is safe and/or effective to improve neurological outcome.

Inclusion Criteria:

• Patients with cerebral embolism.
• NIHSS score is more than (or equal to) 10.
• On day 7 after onset of stroke, the improvement of NIHSS is less than (or equal to) 5, compared with the level at administration.
• Bone marrow aspiration can be done in 10 days after onset of stroke

Exclusion Criteria:

• Patient with cerebral hemorrhage or symptomatic hemorrhagic infarction.
• Patient who expects brain surgery.
• Patient with acute myocardial infarction.
• Patient with coagulation disorder.
• Number of Platelet < 100000/mm3
• Serum creatinine level >2.0mg/dl
• Patient with malignancy.
• Patient with uncontrolled proliferative diabetic retinopathy.
• Patient suspected infective endocarditis.
• HBV, HCV, HIV or HTLV positive